Non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma, is predominantly driven by mutations in driver genes, primarily including anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations (1). This evidence concerns the gene ALK and non-small cell lung carcinoma.